Breaking News Instant updates and real-time market news.

AMRN

Amarin

$16.90

-0.58 (-3.32%)

08:06
11/12/19
11/12
08:06
11/12/19
08:06

Amarin jumps 7% to $18.13 after FDA post briefing docs ahead of panel

  • 14

    Nov

  • 28

    Dec

AMRN Amarin
$16.90

-0.58 (-3.32%)

10/31/19
AGIS
10/31/19
INITIATION
Target $23
AGIS
Buy
Amarin initiated with a Buy at Aegis
Aegis analyst Nathan Weinstein initiated coverage of Amarin with a Buy rating and $23 price target.
10/31/19
10/31/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mistras (MG) initiated with a Buy at Maxim. 2. Paylocity (PCTY) assumed with a Sector Perform at RBC Capital. 3. Transcat (TRNS) resumed with a Buy at Roth Capital. 4. Amarin (AMRN) initiated with a Buy at Aegis. 5. SilverCrest Metals (SILV) initiated with a Neutral at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/05/19
JEFF
11/05/19
NO CHANGE
Target $30
JEFF
Buy
Amarin Q3 Vascepa sales topped consensus, says Jefferies
Jefferies analyst Michael Yee says Amarin this morning reported Q3 Vascepa sales of $112M, in line with his estimate and ahead of consensus at $110M, while its earnings also beat on lower expenses. Guidance was maintained at $380M-$420M and consensus of $408M is already at the upper half, Yee tells investors in a research note. The analyst continues to believe the FDA will be "logical and rational in its review and make a decision that is best for the public given the significant landmark data and the clear benefit/risk formula that favors Vascepa." He keeps a Buy rating on Amarin with a $30 price target. The stock in premarket trading is up 58c to $18.03.
11/06/19
HCWC
11/06/19
NO CHANGE
Target $51
HCWC
Buy
H.C. Wainwright sees 'positive momentum' for Amarin into FDA panel meeting
H.C. Wainwright analyst Andrew Fein says his analysis of the past 30 votes from the Endocrinologic and Metabolic Drugs Advisory Committee panel dating back to 2007 determined that a total of 21 drugs, or 70%, received positive ultimate resolutions of approval, remaining on the market, or being able to continue in development. The analyst sees "positive momentum" heading into the November 14 FDA panel meeting for Amarin. He reiterates a Buy rating on the shares with a $51 price target. The stock closed Tuesday down 12c to $17.33.

TODAY'S FREE FLY STORIES

BHVN

Biohaven Pharmaceutical

$53.79

-0.235 (-0.44%)

05:42
12/06/19
12/06
05:42
12/06/19
05:42
Recommendations
Biohaven Pharmaceutical analyst commentary  »

Biohaven should be owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQUA

Evoqua Water

$19.02

-0.09 (-0.47%)

05:31
12/06/19
12/06
05:31
12/06/19
05:31
Downgrade
Evoqua Water rating change  »

Evoqua Water downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHK

Mohawk

$138.19

3.26 (2.42%)

05:29
12/06/19
12/06
05:29
12/06/19
05:29
Initiation
Mohawk initiated  »

Mohawk initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOS

A.O. Smith

$46.89

0.53 (1.14%)

05:28
12/06/19
12/06
05:28
12/06/19
05:28
Initiation
A.O. Smith initiated  »

A.O. Smith initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEG

Leggett & Platt

$52.16

0.33 (0.64%)

05:27
12/06/19
12/06
05:27
12/06/19
05:27
Initiation
Leggett & Platt initiated  »

Leggett & Platt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OC

Owens Corning

$66.07

0.69 (1.06%)

05:26
12/06/19
12/06
05:26
12/06/19
05:26
Initiation
Owens Corning initiated  »

Owens Corning initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

Jeld-Wen

$23.15

0.47 (2.07%)

05:25
12/06/19
12/06
05:25
12/06/19
05:25
Initiation
Jeld-Wen initiated  »

Jeld-Wen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$46.01

0.445 (0.98%)

05:23
12/06/19
12/06
05:23
12/06/19
05:23
Initiation
Masco initiated  »

Masco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$71.67

1.12 (1.59%)

05:22
12/06/19
12/06
05:22
12/06/19
05:22
Initiation
Installed Building Products initiated  »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$63.90

0.74 (1.17%)

05:22
12/06/19
12/06
05:22
12/06/19
05:22
Initiation
Fortune Brands initiated  »

Fortune Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$144.83

2.825 (1.99%)

05:20
12/06/19
12/06
05:20
12/06/19
05:20
Initiation
Whirlpool initiated  »

Whirlpool initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

AWI

Armstrong World

$93.35

-0.87 (-0.92%)

05:19
12/06/19
12/06
05:19
12/06/19
05:19
Initiation
Armstrong World initiated  »

Armstrong World initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$36.30

-0.3 (-0.82%)

, FB

Facebook

$199.35

0.65 (0.33%)

05:17
12/06/19
12/06
05:17
12/06/19
05:17
Downgrade
Ciena, Facebook, AT&T rating change  »

Ciena downgraded to Sell…

CIEN

Ciena

$36.30

-0.3 (-0.82%)

FB

Facebook

$199.35

0.65 (0.33%)

T

AT&T

$38.21

0.07 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 29

    Jan

RDY

Dr. Reddy's

$40.11

-0.03 (-0.07%)

05:15
12/06/19
12/06
05:15
12/06/19
05:15
Hot Stocks
Dr. Reddy's announces launch of Deferasirox Film-Coated Tablets in U.S. market »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$40.90

0.79 (1.97%)

05:14
12/06/19
12/06
05:14
12/06/19
05:14
Initiation
Toll Brothers initiated  »

Toll Brothers initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PHM

PulteGroup

$40.19

0.79 (2.01%)

05:13
12/06/19
12/06
05:13
12/06/19
05:13
Initiation
PulteGroup initiated  »

PulteGroup initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTH

Meritage Homes

$67.01

0.755 (1.14%)

05:12
12/06/19
12/06
05:12
12/06/19
05:12
Initiation
Meritage Homes initiated  »

Meritage Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$59.82

0.96 (1.63%)

05:11
12/06/19
12/06
05:11
12/06/19
05:11
Initiation
Lennar initiated  »

Lennar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$35.11

0.575 (1.67%)

05:10
12/06/19
12/06
05:10
12/06/19
05:10
Initiation
KB Home initiated  »

KB Home initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$55.73

0.38 (0.69%)

05:09
12/06/19
12/06
05:09
12/06/19
05:09
Initiation
D.R. Horton initiated  »

D.R. Horton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$23.60

-0.48 (-1.99%)

05:06
12/06/19
12/06
05:06
12/06/19
05:06
Downgrade
Summit Materials rating change  »

Summit Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTA

Magenta Therapeutics

$12.99

-0.14 (-1.07%)

05:03
12/06/19
12/06
05:03
12/06/19
05:03
Initiation
Magenta Therapeutics initiated  »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

ODT

Odonate Therapeutics

$33.29

-1.75 (-4.99%)

05:02
12/06/19
12/06
05:02
12/06/19
05:02
Initiation
Odonate Therapeutics initiated  »

Odonate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$10.01

-0.1 (-0.99%)

05:00
12/06/19
12/06
05:00
12/06/19
05:00
Upgrade
Kiniksa rating change  »

Kiniksa assumed to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMED

Amedisys

$165.41

-1.22 (-0.73%)

04:58
12/06/19
12/06
04:58
12/06/19
04:58
Initiation
Amedisys initiated  »

Amedisys initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.